BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344-353. [PMID: 21520200 DOI: 10.1002/hep.24376] [Cited by in Crossref: 431] [Cited by in F6Publishing: 407] [Article Influence: 43.1] [Reference Citation Analysis]
Number Citing Articles
1 Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, Zhang Z, Zhang D, Fan D, Nie Y, Shao F, Wu K, Liang J. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. Journal of Hepatology 2018;68:773-82. [DOI: 10.1016/j.jhep.2017.11.040] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 31.7] [Reference Citation Analysis]
2 Koutoukidis DA, Jebb SA, Aveyard P, Astbury NM. The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial. Obes Facts 2020;13:144-51. [PMID: 32200381 DOI: 10.1159/000505667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
4 Rowe IA. The devotion to surrogate outcomes in drug development for liver disease. Nat Rev Gastroenterol Hepatol 2018;15:1-2. [DOI: 10.1038/nrgastro.2017.155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5:199-207. [PMID: 22570680 DOI: 10.1177/1756283x11430859] [Cited by in Crossref: 108] [Cited by in F6Publishing: 58] [Article Influence: 12.0] [Reference Citation Analysis]
6 Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8:661-668. [PMID: 24683373 DOI: 10.1016/s0016-5085(10)62097-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
8 Kim TY, Lee JG, Sohn JH, Kim JY, Kim SM, Kim J, Jeong WK. Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis. Yonsei Med J 2016;57:138-45. [PMID: 26632394 DOI: 10.3349/ymj.2016.57.1.138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:117-23. [PMID: 31523999 DOI: 10.1080/13543784.2020.1668375] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
10 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
11 Lacasse MC, Tang A, Dubois J, Alvarez F, Spahis S, Chagnon M, Deschênes S, Levy E. Monitoring the efficacy of omega-3 supplementation on liver steatosis and carotid intima-media thickness: a pilot study. Obes Sci Pract 2017;3:201-11. [PMID: 28702213 DOI: 10.1002/osp4.91] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zarei A, Stasi C, Mahmoodi M, Masoumi SJ, Zare M, Jalali M. Effect of soy consumption on liver enzymes, lipid profile, anthropometry indices, and oxidative stress in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Iran J Basic Med Sci 2020;23:1245-50. [PMID: 33149855 DOI: 10.22038/ijbms.2020.46854.10797] [Reference Citation Analysis]
13 Siwatch S, Singh V, Dhaliwal LK, Kumari S, Singh K. Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women. J Obstet Gynaecol 2021;:1-5. [PMID: 34689689 DOI: 10.1080/01443615.2021.1969346] [Reference Citation Analysis]
14 Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Fan JG. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 2014; 20(16): 4702-4711 [PMID: 24782622 DOI: 10.3748/wjg.v20.i16.4702] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 62] [Article Influence: 9.4] [Reference Citation Analysis]
15 Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 2013; 19(1): 57-64 [PMID: 23326163 DOI: 10.3748/wjg.v19.i1.57] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 62] [Article Influence: 8.5] [Reference Citation Analysis]
16 Zhuang Z, Qu H, Yang W, Liu J, Wang F, Liu Y, Ding J, Shi J. Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method. Ann Hepatol. 2020;19:313-319. [PMID: 31870745 DOI: 10.1016/j.aohep.2019.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, Ningarhari M, Louvet A, Leteurtre E, Raverdy V, Dharancy S, Pattou F, Mathurin P. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020. [PMID: 32553765 DOI: 10.1053/j.gastro.2020.06.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 50.0] [Reference Citation Analysis]
18 Marin-Alejandre BA, Cantero I, Perez-Diaz-Del-Campo N, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Abete I, Zulet MA. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver Int 2021;41:1532-44. [PMID: 33550706 DOI: 10.1111/liv.14818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Angulo P. Trial design in NASH—realities and challenges. Nat Rev Gastroenterol Hepatol 2011;8:424-5. [DOI: 10.1038/nrgastro.2011.125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Dennis A, Mouchti S, Kelly M, Fallowfield JA, Hirschfield G, Pavlides M, Banerjee R. A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. Sci Rep 2020;10:15308. [PMID: 32943694 DOI: 10.1038/s41598-020-71995-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
22 Chen YM, Liu Y, Zhou RF, Chen XL, Wang C, Tan XY, Wang LJ, Zheng RD, Zhang HW, Ling WH, Zhu HL. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076. [PMID: 26743949 DOI: 10.1038/srep19076] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 24.4] [Reference Citation Analysis]
23 Shenoy-Bhangle A, Baliyan V, Kordbacheh H, Guimaraes AR, Kambadakone A. Diffusion weighted magnetic resonance imaging of liver: Principles, clinical applications and recent updates. World J Hepatol 2017; 9(26): 1081-1091 [PMID: 28989564 DOI: 10.4254/wjh.v9.i26.1081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
24 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, Kim CW, Jo SH, Lee CD, Lee YS, Choi SW, Yang JM, Jang JW, Kim SG, Jung SW, Kim HK, Chae HB, Yoon SK. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:120-30. [PMID: 23837136 DOI: 10.3350/cmh.2013.19.2.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
25 Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs 2020;29:151-61. [PMID: 31847612 DOI: 10.1080/13543784.2020.1703949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
26 Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes Obes Metab 2021. [PMID: 34622555 DOI: 10.1111/dom.14569] [Reference Citation Analysis]
27 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
28 Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc. 2019;78:290-304. [PMID: 30924429 DOI: 10.1017/s0029665119000570] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
29 El‐deen RM, Heeba GH, Abdel‐latif RG, Khalifa MM. Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high‐fat diet‐induced nonalcoholic fatty liver in rats. Fundam Clin Pharmacol 2020;34:353-64. [DOI: 10.1111/fcp.12530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Forsgren MF, Nasr P, Karlsson M, Dahlström N, Norén B, Ignatova S, Sinkus R, Cedersund G, Leinhard OD, Ekstedt M, Kechagias S, Lundberg P. Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scand J Gastroenterol 2020;55:848-59. [PMID: 32684060 DOI: 10.1080/00365521.2020.1786599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Yugawa K, Itoh S, Iseda N, Kurihara T, Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Yoshizumi T, Mori M. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status. Sci Rep 2021;11:5845. [PMID: 33712681 DOI: 10.1038/s41598-021-85186-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Langford CR, Goldinger MH, Treanor D, McGenity C, Dillman JR, Allende DS, Goldin R, Brunt EM, Zatloukal K, Denk H, Fleming KA. Improved pathology reporting in NAFLD/NASH for clinical trials. J Clin Pathol 2021:jclinpath-2021-207967. [PMID: 34753791 DOI: 10.1136/jclinpath-2021-207967] [Reference Citation Analysis]
33 Bril F, Millán L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez-Arranz I, Alonso C, Ortiz Betes P, Mato JM, Cusi K. Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2018;20:1702-9. [PMID: 29527789 DOI: 10.1111/dom.13285] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
34 Buzzetti E, Petta S, Manuguerra R, Luong TV, Cabibi D, Corradini E, Craxì A, Pinzani M, Tsochatzis E, Pietrangelo A. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. Liver Int 2019;39:1325-34. [PMID: 30851216 DOI: 10.1111/liv.14096] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
35 Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-775. [PMID: 26600078 DOI: 10.1002/hep.28356 doi: 10.1002/hep.28356] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Del Ben M, Overi D, Polimeni L, Carpino G, Labbadia G, Baratta F, Pastori D, Noce V, Gaudio E, Angelico F, Mancone C. Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. Int J Mol Sci 2018;19:E603. [PMID: 29463024 DOI: 10.3390/ijms19020603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
37 Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, Mathurin P, Gournay J, Nguyen-khac E, De Ledinghen V, Larrey D, Tran A, Bourliere M, Maynard-muet M, Asselah T, Henrion J, Nevens F, Cassiman D, Geerts A, Moreno C, Beuers U, Galle P, Spengler U, Bugianesi E, Craxi A, Angelico M, Fargion S, Voiculescu M, Gheorghe L, Preotescu L, Caballeria J, Andrade R, Crespo J, Callera J, Ala A, Aithal G, Abouda G, Luketic V, Huang M, Gordon S, Pockros P, Poordad F, Shores N, Moehlen M, Bambha K, Clark V, Satapathy S, Parekh S, Reddy R, Sheikh M, Szabo G, Vierling J, Foster T, Umpierrez G, Chang C, Box T, Gallegos-orozco J. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016;150:1147-1159.e5. [DOI: 10.1053/j.gastro.2016.01.038] [Cited by in Crossref: 533] [Cited by in F6Publishing: 499] [Article Influence: 106.6] [Reference Citation Analysis]
38 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. [DOI: 10.1002/hep.27368] [Cited by in Crossref: 1010] [Cited by in F6Publishing: 919] [Article Influence: 168.3] [Reference Citation Analysis]
39 Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Pharmacoeconomics 2020;38:485-97. [PMID: 31919793 DOI: 10.1007/s40273-019-00881-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther 2021;54:1472-80. [PMID: 34694013 DOI: 10.1111/apt.16674] [Reference Citation Analysis]
41 Caputo T, Gilardi F, Desvergne B. From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. FEBS Lett 2017;591:3061-88. [DOI: 10.1002/1873-3468.12742] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 13.8] [Reference Citation Analysis]
42 Shin HK, Park JH, Yu JH, Jin YJ, Suh YJ, Lee JW, Kim W; Korean Nonalcoholic Fatty Liver Study Group (KNSG). Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease. Sci Rep 2021;11:18004. [PMID: 34504179 DOI: 10.1038/s41598-021-97385-2] [Reference Citation Analysis]
43 Galarregui C, Marin-Alejandre BA, Perez-Diaz-Del-Campo N, Cantero I, Monreal JI, Elorz M, Benito-Boillos A, Herrero JI, Tur JA, Martínez JA, Zulet MA, Abete I. Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. Diagnostics (Basel) 2020;10:E917. [PMID: 33171699 DOI: 10.3390/diagnostics10110917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS. Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:1831-1841.e5. [PMID: 31734449 DOI: 10.1016/j.cgh.2019.11.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
45 Kahl S, Pützer J, Roden M. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Semin Liver Dis 2021. [PMID: 34289506 DOI: 10.1055/s-0041-1732354] [Reference Citation Analysis]
46 Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int 2021;41:261-70. [PMID: 32946642 DOI: 10.1111/liv.14669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
47 Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22:292-299. [PMID: 23512725 DOI: 10.1002/oby.20426] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
48 Holmgren G, Ulfenborg B, Asplund A, Toet K, Andersson CX, Hammarstedt A, Hanemaaijer R, Küppers-Munther B, Synnergren J. Characterization of Human Induced Pluripotent Stem Cell-Derived Hepatocytes with Mature Features and Potential for Modeling Metabolic Diseases. Int J Mol Sci 2020;21:E469. [PMID: 31940797 DOI: 10.3390/ijms21020469] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
49 Bril F, Barb D, Portillo-sanchez P, Biernacki D, Lomonaco R, Suman A, Weber MH, Budd JT, Lupi ME, Cusi K. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology 2017;65:1132-44. [DOI: 10.1002/hep.28985] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 26.3] [Reference Citation Analysis]
50 Naito H, Yoshikawa-Bando Y, Yuan Y, Hashimoto S, Kitamori K, Yatsuya H, Nakajima T. High-fat and high-cholesterol diet decreases phosphorylated inositol-requiring kinase-1 and inhibits autophagy process in rat liver. Sci Rep 2019;9:12514. [PMID: 31467308 DOI: 10.1038/s41598-019-48973-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Majeed M, Majeed S, Nagabhushanam K, Lawrence L, Mundkur L. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. Sci Rep 2020;10:7440. [PMID: 32366854 DOI: 10.1038/s41598-020-64293-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
52 Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 2013;48:1051-1060. [PMID: 23184095 DOI: 10.1007/s00535-012-0704-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
53 Mueller JL, Feeney ER, Zheng H, Misdraji J, Kruger AJ, Alatrakchi N, King LY, Gelrud L, Corey KE, Chung RT. Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2015;6:e114. [PMID: 26448455 DOI: 10.1038/ctg.2015.36] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
54 Suzuki R, Koike Y, Ota M, Endo T, Hisada Y, Tsujimoto T, Kanayama M, Ito YM, Sudo H, Iwata A, Yamada K, Iwasaki N, Takahata M. Thrombocytopenia Associated with Unrecognized Non-Alcoholic Fatty Liver Disease Is an Independent Predictor of Perioperative Significant Blood Loss in Cervical Laminoplasty. World Neurosurg 2021;155:e797-804. [PMID: 34509679 DOI: 10.1016/j.wneu.2021.09.012] [Reference Citation Analysis]
55 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
56 Francque S, Vonghia L. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Adv Ther 2019;36:1052-74. [PMID: 30888594 DOI: 10.1007/s12325-019-00898-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
57 Gu W, Wen K, Yan C, Li S, Liu T, Xu C, Liu L, Zhao M, Zhang J, Geng T, Gong D. Maintaining intestinal structural integrity is a potential protective mechanism against inflammation in goose fatty liver. Poult Sci 2020;99:5297-307. [PMID: 33142445 DOI: 10.1016/j.psj.2020.08.052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
59 Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809-820. [PMID: 25873078 DOI: 10.1177/1535370215579161] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
60 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
62 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. Hepatology Research 2021;51:406-16. [DOI: 10.1111/hepr.13600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Matono T, Kato J, Tokunaga S, Sugihara T, Hiramatsu A, Hyogo H, Tobita H, Sato S, Kawanaka M, Hara Y, Hino K, Chayama K, Murawaki Y, Isomoto H. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. PLoS One 2020;15:e0219412. [PMID: 32106257 DOI: 10.1371/journal.pone.0219412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
64 Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, Alhaddad R, Alkhouri N. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9. [DOI: 10.1007/s12072-015-9679-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
65 Andrews DB, Lavine JE. Medical therapy for nonalcoholic fatty liver disease in children and adolescents. Expert Rev Gastroenterol Hepatol 2012;6:1-3. [PMID: 22149573 DOI: 10.1586/egh.11.72] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
66 Ilan Y. Immune therapy for nonalcoholic steatohepatitis: are we there yet? J Clin Gastroenterol. 2013;47:298-307. [PMID: 23442833 DOI: 10.1097/mcg.0b013e31827873dc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
67 Nahar S, Nakashima Y, Miyagi-Shiohira C, Kinjo T, Toyoda Z, Kobayashi N, Saitoh I, Watanabe M, Noguchi H, Fujita J. Cytokines in adipose-derived mesenchymal stem cells promote the healing of liver disease. World J Stem Cells 2018; 10(11): 146-159 [PMID: 30631390 DOI: 10.4252/wjsc.v10.i11.146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
68 Rudolph B, Bjorklund N, Ovchinsky N, Kogan-Liberman D, Perez A, Liszewski M, Levin TL, Ewart M, Liu Q, Xue X, Viswanathan S, Strickler HD. Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design. Contemp Clin Trials 2018;75:51-8. [PMID: 30401631 DOI: 10.1016/j.cct.2018.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
69 Bedossa P, Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1811-1822.e4. [PMID: 27003601 DOI: 10.1053/j.gastro.2016.03.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 12.8] [Reference Citation Analysis]
70 Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL. Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. Anal Cell Pathol (Amst) 2014;2014:526979. [PMID: 25763333 DOI: 10.1155/2014/526979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
71 Ogawa Y, Imajo K, Yoneda M, Kessoku T, Tomeno W, Shinohara Y, Kato S, Mawatari H, Nozaki Y, Fujita K, Kirikoshi H, Maeda S, Saito S, Wada K, Nakajima A. Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One 2013;8:e65211. [PMID: 23762319 DOI: 10.1371/journal.pone.0065211] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
72 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
73 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
74 Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550-556. [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027] [Cited by in Crossref: 277] [Cited by in F6Publishing: 258] [Article Influence: 34.6] [Reference Citation Analysis]
75 Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, Perseghin G. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest 2018;41:509-21. [DOI: 10.1007/s40618-017-0799-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
76 Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease. PLoS One. 2011;6:e23937. [PMID: 21886843 DOI: 10.1371/journal.pone.0023937;] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Kucukoglu O, Guldiken N, Chen Y, Usachov V, El-Heliebi A, Haybaeck J, Denk H, Trautwein C, Strnad P. High-fat diet triggers Mallory-Denk body formation through misfolding and crosslinking of excess keratin 8. Hepatology. 2014;60:169-178. [PMID: 24519272 DOI: 10.1002/hep.27068] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
78 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22(32): 7236-7251 [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 98] [Article Influence: 21.2] [Reference Citation Analysis]
79 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 304] [Cited by in F6Publishing: 267] [Article Influence: 76.0] [Reference Citation Analysis]
80 Weiss TS, Lupke M, Ibrahim S, Buechler C, Lorenz J, Ruemmele P, Hofmann U, Melter M, Dayoub R. Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways. PLoS One 2017;12:e0184282. [PMID: 28877220 DOI: 10.1371/journal.pone.0184282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
81 Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Research and Clinical Practice 2020;170:108487. [DOI: 10.1016/j.diabres.2020.108487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
82 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
83 Xu N, Xie Q, Li J, Gao Y, Li X. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. J Int Med Res 2020;48:300060520903667. [PMID: 32070159 DOI: 10.1177/0300060520903667] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, Irvine K, Clouston AD. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393-1405. [PMID: 24254368 DOI: 10.1002/hep.26937] [Cited by in Crossref: 197] [Cited by in F6Publishing: 186] [Article Influence: 28.1] [Reference Citation Analysis]
85 Ryu KJ, Park H, Park JS, Lee YW, Kim SY, Kim H, Jeong Y, Kim YJ, Yi KW, Shin JH, Hur JY, Kim T. Vasomotor Symptoms: More Than Temporary Menopausal Symptoms. J Menopausal Med 2020;26:147-53. [PMID: 33423402 DOI: 10.6118/jmm.20030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM, Michalak S, Bonnafous S, Michielsen P, Oberti F, Iannelli A, Van Gaal L, Patouraux S, Blanchet O, Verrijken A, Gual P, Rousselet M, Driessen A, Hunault G, Bertrais S, Tran A, Calès P, Francque S. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther 2018;47:1387-96. [DOI: 10.1111/apt.14621] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
87 Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol 2015; 7(25): 2597-2602 [PMID: 26557952 DOI: 10.4254/wjh.v7.i25.2597] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
88 Yoneda M. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases: Editorial. Hepatol Res 2013;43:1125-6. [DOI: 10.1111/hepr.12111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
89 Seymour KA, Abdelmalek MF. The role of bariatric surgery in the management of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2021;37:208-15. [PMID: 33769376 DOI: 10.1097/MOG.0000000000000721] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Augustin S, Graupera I, Caballeria J; en nombre del grupo de trabajo sobre «Hígado graso no alcohólico» de la Societat Catalana de Digestologia. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc) 2017;149:542-8. [PMID: 28751080 DOI: 10.1016/j.medcli.2017.06.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
91 Popov VB, Thompson CC, Kumar N, Ciarleglio MM, Deng Y, Laine L. Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis. Dig Dis Sci 2016;61:2477-87. [DOI: 10.1007/s10620-016-4178-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
92 Alkayyali T, Qutranji L, Kaya E, Bakir A, Yilmaz Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol 2020;57:613-8. [PMID: 31897769 DOI: 10.1007/s00592-019-01467-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
93 Wáng YXJ, Wang X, Wu P, Wang Y, Chen W, Chen H, Li J. Topics on quantitative liver magnetic resonance imaging. Quant Imaging Med Surg 2019;9:1840-90. [PMID: 31867237 DOI: 10.21037/qims.2019.09.18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
94 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 34.3] [Reference Citation Analysis]
95 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
96 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
97 Yilmaz Y, Eren F. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2014;26:1292-5. [DOI: 10.1097/meg.0000000000000184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
98 Koutoukidis DA, Morris E, Henry JA, Shammoon Y, Zimmerman M, Michalopoulou M, Jebb SA, Aveyard P. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. PLoS One 2021;16:e0250385. [PMID: 33882107 DOI: 10.1371/journal.pone.0250385] [Reference Citation Analysis]
99 Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-75. [PMID: 26600078 DOI: 10.1002/hep.28356] [Cited by in Crossref: 512] [Cited by in F6Publishing: 488] [Article Influence: 102.4] [Reference Citation Analysis]
100 Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.J Clin Endocrinol Metab. 2017;102:2950-2961. [PMID: 28575232 DOI: 10.1210/jc.2017-00867] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
101 Kamata Y, Kessoku T, Shimizu T, Kobayashi T, Kurihashi T, Sato S, Kuraji S, Aoyama N, Iwasaki T, Takashiba S, Hamada N, Kodama T, Tamura T, Ino S, Higurashi T, Taguri M, Yamanaka T, Yoneda M, Usuda H, Wada K, Nakajima A, Minabe M. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial. Trials 2020;21:291. [PMID: 32293522 DOI: 10.1186/s13063-020-4201-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
102 Van Beers BE. Science to Practice: can we diagnose nonalcoholic steatohepatitis with intravoxel incoherent motion diffusion-weighted MR imaging? Radiology 2014;270:1-2. [PMID: 24354367 DOI: 10.1148/radiol.13132294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
103 Corey KE, Lai M, Gelrud LG, Misdraji J, Barlow LL, Zheng H, Andersson KL, Thiim M, Pratt DS, Chung RT. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2012;10:651-656. [PMID: 22330232 DOI: 10.1016/j.cgh.2012.01.017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
104 Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases 2020; 8(21): 5235-5249 [PMID: 33269259 DOI: 10.12998/wjcc.v8.i21.5235] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
105 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 171] [Article Influence: 37.2] [Reference Citation Analysis]
106 Morita S, Neto Dde S, Morita FH, Morita NK, Lobo SM. Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. Obes Surg 2015;25:2335-43. [PMID: 25920616 DOI: 10.1007/s11695-015-1696-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
107 Marin-Alejandre BA, Abete I, Cantero I, Riezu-Boj JI, Milagro FI, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martínez JA, Zulet MA. Association between Sleep Disturbances and Liver Status in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Comparison with Healthy Controls. Nutrients 2019;11:E322. [PMID: 30717355 DOI: 10.3390/nu11020322] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
108 Kessoku T, Imajo K, Kobayashi T, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Saito S, Nakajima A. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. Contemporary Clinical Trials 2018;69:40-7. [DOI: 10.1016/j.cct.2018.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Ha Y, Seo N, Shim JH, Kim SY, Park JA, Han S, Kim KW, Yu E, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol. 2015;30:1666-1672. [PMID: 25974139 DOI: 10.1111/jgh.12996] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
110 Fermin CR, Lee AM, Filipp SL, Gurka MJ, DeBoer MD. Serum Alanine Aminotransferase Trends and Their Relationship with Obesity and Metabolic Syndrome in United States Adolescents, 1999-2014. Metab Syndr Relat Disord 2017;15:276-82. [PMID: 28520503 DOI: 10.1089/met.2017.0023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
111 Adams LA. Accurate quantification of hepatic fat—is it important? Nat Rev Gastroenterol Hepatol 2015;12:126-7. [DOI: 10.1038/nrgastro.2015.23] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
112 Koch M, Borggrefe J, Barbaresko J, Groth G, Jacobs G, Siegert S, Lieb W, Müller MJ, Bosy-Westphal A, Heller M, Nöthlings U. Dietary patterns associated with magnetic resonance imaging-determined liver fat content in a general population study. Am J Clin Nutr 2014;99:369-77. [PMID: 24305680 DOI: 10.3945/ajcn.113.070219] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
113 Baratta F, Pastori D, Del Ben M, Polimeni L, Labbadia G, Di Santo S, Piemonte F, Tozzi G, Violi F, Angelico F. Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. EBioMedicine. 2015;2:750-754. [PMID: 26288848 DOI: 10.1016/j.ebiom.2015.05.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
114 Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, Correa M, Lo M, Suman A, Cusi K. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J Hepatol 2015;62:405-11. [PMID: 25195551 DOI: 10.1016/j.jhep.2014.08.040] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 10.1] [Reference Citation Analysis]
115 Adibi A, Maleki S, Adibi P, Etminani R, Hovsepian S. Prevalence of Nonalcoholic Fatty Liver Disease and its Related Metabolic Risk Factors in Isfahan, Iran. Adv Biomed Res 2017;6:47. [PMID: 28503502 DOI: 10.4103/2277-9175.204590] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
116 VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, Lloyd-Jones DM, Terrault NA, Siddique J. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;153:1260-1272.e3. [PMID: 28802566 DOI: 10.1053/j.gastro.2017.08.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
117 Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300-1306. [PMID: 21750883 DOI: 10.1007/s00535-011-0436-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
118 Cheng S, Ge J, Zhao C, Le S, Yang Y, Ke D, Wu N, Tan X, Zhang X, Du X, Sun J, Wang R, Shi Y, Borra RJH, Parkkola R, Wiklund P, Lu D. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial. Sci Rep 2017;7:15952. [PMID: 29162875 DOI: 10.1038/s41598-017-16159-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
119 Zeng H, Larson KJ, Cheng WH, Bukowski MR, Safratowich BD, Liu Z, Hakkak R. Advanced liver steatosis accompanies an increase in hepatic inflammation, colonic, secondary bile acids and Lactobacillaceae/Lachnospiraceae bacteria in C57BL/6 mice fed a high-fat diet. J Nutr Biochem 2020;78:108336. [PMID: 32004929 DOI: 10.1016/j.jnutbio.2019.108336] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
120 Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis. 2012;16:631-645. [PMID: 22824485 DOI: 10.1016/j.cld.2012.05.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
121 Qiu Y, Wang S, Wan T, Ye M, Jiang R, Pei L, Yang L. Blood-based novel biomarkers for nonalcoholic steatohepatitis. Biomark Med 2018;12:501-15. [PMID: 29712439 DOI: 10.2217/bmm-2017-0361] [Reference Citation Analysis]
122 Soon G, Wee A. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. Clin Mol Hepatol 2021;27:44-57. [PMID: 33207115 DOI: 10.3350/cmh.2020.0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
123 Otte CM, Rothuizen J, Favier RP, Penning LC, Vreman S. A morphological and immunohistochemical study of the effects of prednisolone or ursodeoxycholic acid on liver histology in feline lymphocytic cholangitis. J Feline Med Surg 2014;16:796-804. [PMID: 24496321 DOI: 10.1177/1098612X14520811] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
124 Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clin Gastroenterol Hepatol 2019; 17: 2310-2319. e6. [PMID: 30708111 DOI: 10.1016/j.cgh.2019.01.027] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]
125 Mandelia C, Collyer E, Mansoor S, Lopez R, Lappe S, Nobili V, Alkhouri N. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2016;63:181-187. [PMID: 26835904 DOI: 10.1097/mpg.0000000000001136] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
126 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 120.0] [Reference Citation Analysis]
127 Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V, Consortium E-C. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology. 2013;144:1426-1437. [PMID: 23474284 DOI: 10.1053/j.gastro.2013.02.042] [Cited by in Crossref: 1303] [Cited by in F6Publishing: 1142] [Article Influence: 162.9] [Reference Citation Analysis]
128 Rowe IA, Parker R. Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials. Gastroenterology 2015;148:262. [PMID: 25451662 DOI: 10.1053/j.gastro.2014.09.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
129 Cassinotto C, Boursier J, Paisant A, Guiu B, Irles-Depe M, Canivet C, Aube C, de Ledinghen V. Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD. Hepatology 2021;73:2196-205. [PMID: 33236409 DOI: 10.1002/hep.31655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Lee I, Cho J, Park J, Kang H. Association of hand-grip strength and non-alcoholic fatty liver disease index in older adults. J Exerc Nutrition Biochem 2018;22:62-8. [PMID: 30661332 DOI: 10.20463/jenb.2018.0031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
131 Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 2016;65:1080-6. [PMID: 26775559 DOI: 10.1016/j.metabol.2015.11.008] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 15.3] [Reference Citation Analysis]
132 Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 2014;18:73-89. [DOI: 10.1016/j.cld.2013.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
133 Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Zulet MA. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients 2019;11:E2543. [PMID: 31652512 DOI: 10.3390/nu11102543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
134 Sethunath D, Morusu S, Tuceryan M, Cummings OW, Zhang H, Yin XM, Vanderbeck S, Chalasani N, Gawrieh S. Automated assessment of steatosis in murine fatty liver. PLoS One 2018;13:e0197242. [PMID: 29746543 DOI: 10.1371/journal.pone.0197242] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Gesnik M, Bhatt M, Roy Cardinal MH, Destrempes F, Allard L, Nguyen BN, Alquier T, Giroux JF, Tang A, Cloutier G. In vivo Ultrafast Quantitative Ultrasound and Shear Wave Elastography Imaging on Farm-Raised Duck Livers during Force Feeding. Ultrasound Med Biol 2020;46:1715-26. [PMID: 32381381 DOI: 10.1016/j.ultrasmedbio.2020.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
136 Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815-823. [PMID: 22966992 DOI: 10.1111/apt.12046] [Cited by in Crossref: 119] [Cited by in F6Publishing: 124] [Article Influence: 14.9] [Reference Citation Analysis]
137 Shin J, Yu JH, Jin YJ, Chae MH, Yoon CH, Lee JW. Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. Medicine (Baltimore) 2019;98:e18020. [PMID: 31764818 DOI: 10.1097/MD.0000000000018020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Hameed B, Terrault N. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:365-85. [PMID: 27063275 DOI: 10.1016/j.cld.2015.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
139 Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K. Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. J Clin Endocrinol Metab 2021:dgab417. [PMID: 34190318 DOI: 10.1210/clinem/dgab417] [Reference Citation Analysis]
140 Suresh RR, Jain S, Chen Z, Tosh DK, Ma Y, Podszun MC, Rotman Y, Salvemini D, Jacobson KA. Design and in vivo activity of A3 adenosine receptor agonist prodrugs. Purinergic Signal 2020;16:367-77. [PMID: 32720036 DOI: 10.1007/s11302-020-09715-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
141 Cassinotto C, Boursier J, de Lédinghen V, Lebigot J, Lapuyade B, Cales P, Hiriart J, Michalak S, Bail BL, Cartier V, Mouries A, Oberti F, Fouchard-hubert I, Vergniol J, Aubé C. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy: Cassinotto et al. Hepatology 2016;63:1817-27. [DOI: 10.1002/hep.28394] [Cited by in Crossref: 235] [Cited by in F6Publishing: 204] [Article Influence: 47.0] [Reference Citation Analysis]
142 Loomba R. Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2014;12:1731-2. [PMID: 24703861 DOI: 10.1016/j.cgh.2014.03.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
143 Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, (JSG-NAFLD) TOJSGON. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(29): 10108-10114 [PMID: 25110437 DOI: 10.3748/wjg.v20.i29.10108] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
144 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
145 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Verbeek J, Spincemaille P, Vanhorebeek I, Van den Berghe G, Vander Elst I, Windmolders P, van Pelt J, van der Merwe S, Bedossa P, Nevens F, Cammue B, Thevissen K, Cassiman D. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. Lipids Health Dis. 2017;16:46. [PMID: 28231800 DOI: 10.1186/s12944-017-0432-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
147 Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, Tsai CC, Ho MC, Lee WC, Yu HC, Shen YY, Eng HL, Wang J, Tseng HH, Jeng YM, Yeh CT, Chen CL, Chen PJ, Liaw YF. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol Commun 2018;2:747-59. [PMID: 29881825 DOI: 10.1002/hep4.1182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
148 Ni X, Jiao L, Zhang Y, Xu J, Zhang Y, Zhang X, Du Y, Sun Z, Wang S. Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. Int J Gen Med 2021;14:3439-44. [PMID: 34285567 DOI: 10.2147/IJGM.S317081] [Reference Citation Analysis]
149 Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 2013;268:132-40. [PMID: 23391614 DOI: 10.1016/j.taap.2013.01.022] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 11.8] [Reference Citation Analysis]
150 Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;37:720-729. [PMID: 23441892 DOI: 10.1111/apt.12255] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
151 Spearman CW, Afihene M, Betiku O, Bobat B, Cunha L, Kassianides C, Katsidzira L, Mekonnen HD, Ocama P, Ojo O, Paruk I, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1036-46. [PMID: 34508671 DOI: 10.1016/S2468-1253(21)00275-2] [Reference Citation Analysis]
152 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1902] [Article Influence: 228.6] [Reference Citation Analysis]
153 Yan H, Wu W, Yang Y, Wu Y, Yang Q, Shi Y. A novel integrated Model for End-Stage Liver Disease model predicts short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure patients. Hepatol Res. 2015;45:405-414. [PMID: 24849735 DOI: 10.1111/hepr.12362] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
154 Nalbantoglu I, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(27): 9026-9037 [PMID: 25083076 DOI: 10.3748/wjg.v20.i27.9026] [Cited by in F6Publishing: 51] [Reference Citation Analysis]
155 Dichtel LE, Corey KE, Misdraji J, Bredella MA, Schorr M, Osganian SA, Young BJ, Sung JC, Miller KK. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2017;8:e217. [PMID: 28125073 DOI: 10.1038/ctg.2016.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
156 Wu SD, Li L, Wang JY. Ursodeoxycholic acid for nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2012;24:1247-1253. [PMID: 22864259 DOI: 10.1097/meg.0b013e3283572ec0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
157 He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016;95:e4947. [PMID: 27759627 DOI: 10.1097/MD.0000000000004947] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
158 Rashu EB, Werge MP, Hetland LE, Junker AE, Jensen MK, Gluud LL. Referral Patterns for Patients with Nonalcoholic Fatty Liver Disease. J Clin Med 2021;10:404. [PMID: 33494361 DOI: 10.3390/jcm10030404] [Reference Citation Analysis]
159 Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, Molleston JP, Chalasani N, Sanyal AJ, Fishbein MH, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. J Pediatr 2017;187:141-146.e1. [PMID: 28366357 DOI: 10.1016/j.jpeds.2017.03.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
160 Ikura Y. Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades. World J Hepatol 2014; 6(12): 894-900 [PMID: 25544876 DOI: 10.4254/wjh.v6.i12.894] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
161 Liu Y, Han T, Zhu Z, Li Y. Thymosinβ4: A novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient? Clinics and Research in Hepatology and Gastroenterology 2014;38:310-7. [DOI: 10.1016/j.clinre.2014.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
162 Kapoor N, Audsley J, Rupali P, Sasadeusz J, Paul TV, Thomas N, Lewin SR. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. AIDS 2019;33:1105-15. [PMID: 31045941 DOI: 10.1097/QAD.0000000000002161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
163 Ji Y, Elkin K, Yip J, Guan L, Han W, Ding Y. From circadian clocks to non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2019;13:1107-12. [DOI: 10.1080/17474124.2019.1684899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
164 Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur J Pharmacol 2020;870:172913. [PMID: 31926994 DOI: 10.1016/j.ejphar.2020.172913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
165 Noureddin M, Loomba R. Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis (Hoboken) 2012;1:104-7. [PMID: 31186861 DOI: 10.1002/cld.65] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
166 Martínez LA, Larrieta E, Kershenobich D, Torre A. The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population. Ann Hepatol 2017;16:909-15. [PMID: 29055919 DOI: 10.5604/01.3001.0010.5282] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
167 Cordeiro A, Costa R, Andrade N, Silva C, Canabrava N, Pena MJ, Rodrigues I, Andrade S, Ramalho A. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity? Clin Res Hepatol Gastroenterol 2020;44:394-402. [PMID: 32044284 DOI: 10.1016/j.clinre.2019.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
168 Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. PLoS One 2021;16:e0251449. [PMID: 34077443 DOI: 10.1371/journal.pone.0251449] [Reference Citation Analysis]
169 Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012;56:1363-1370. [PMID: 22314419 DOI: 10.1016/j.jhep.2011.12.025] [Cited by in Crossref: 141] [Cited by in F6Publishing: 121] [Article Influence: 15.7] [Reference Citation Analysis]
170 Gorst SL, Prinsen CA, Salcher-konrad M, Matvienko-sikar K, Williamson PR, Terwee CB. Methods used in the selection of instruments for outcomes included in core outcome sets have improved since the publication of the COSMIN/COMET guideline. Journal of Clinical Epidemiology 2020;125:64-75. [DOI: 10.1016/j.jclinepi.2020.05.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
171 Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Lazo-Del Vallin S, Diago M, Adams LA, Romero-Gomez M, Chalasani N. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2017;45:332-344. [PMID: 27862096 DOI: 10.1111/apt.13860] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
172 Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C, Colca JR, Iwashita J, Koch GG, Dittrich HC. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322-1332. [PMID: 32610115 DOI: 10.1016/j.jhep.2020.06.025] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 46.0] [Reference Citation Analysis]
173 Yilmaz Y, Ozturk O, Alahdab YO, Senates E, Colak Y, Doganay HL, Coskunpinar E, Oltulu YM, Eren F, Atug O, Tuncer I, Imeryuz N. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis 2013;45:58-62. [PMID: 22995553 DOI: 10.1016/j.dld.2012.08.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
174 Gawrieh S, Chalasani N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:338-48. [PMID: 26378648 DOI: 10.1055/s-0035-1562951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
175 Bruckbauer A, Banerjee J, Fu L, Li F, Cao Q, Cui X, Wu R, Shi H, Xue B, Zemel MB. A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice. Int J Hepatol 2016;2016:9185987. [PMID: 28042486 DOI: 10.1155/2016/9185987] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
176 Astbury S, Grove JI, Dorward DA, Guha IN, Fallowfield JA, Kendall TJ. Reliable computational quantification of liver fibrosis is compromised by inherent staining variation. J Pathol Clin Res 2021;7:471-81. [PMID: 34076968 DOI: 10.1002/cjp2.227] [Reference Citation Analysis]
177 Pearlman M, Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014;30:223-237. [PMID: 24717764 DOI: 10.1097/mog.0000000000000060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
178 Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, Suman A, Weber M, Cusi K. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61:153-160. [PMID: 25145475 DOI: 10.1002/hep.27395] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 14.0] [Reference Citation Analysis]
179 Lee SY, Sung JH. Gut-liver on a chip toward an in vitro model of hepatic steatosis. Biotechnol Bioeng 2018;115:2817-27. [PMID: 29981260 DOI: 10.1002/bit.26793] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
180 Schattenberg JM, Straub BK. On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. J Hepatol 2020;73:1592-3. [PMID: 32933780 DOI: 10.1016/j.jhep.2020.07.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
181 Friedman S, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L, Ratziu V. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016;47:356-365. [PMID: 26944023 DOI: 10.1016/j.cct.2016.02.012] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 27.0] [Reference Citation Analysis]
182 Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Emerging drugs for non-alcoholic steatohepatitis. Expert Opin Emerg Drugs. 2013;18:279-290. [PMID: 23848366 DOI: 10.1517/14728214.2013.811232] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
183 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
184 Sakamoto M, Tsujikawa H, Effendi K, Ojima H, Harada K, Zen Y, Kondo F, Nakano M, Kage M, Sumida Y, Hashimoto E, Yamada G, Okanoue T, Koike K. Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Pathol Int. 2017;67:1-7. [PMID: 27995687 DOI: 10.1111/pin.12485] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
185 Pampanini V, Inzaghi E, Germani D, Alterio A, Puglianiello A, Alisi A, Nobili V, Cianfarani S. Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2018;28:71-6. [PMID: 29122442 DOI: 10.1016/j.numecd.2017.09.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
186 Shavakhi A, Torki M, Khodadoostan M, Shavakhi S. Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial. Adv Biomed Res 2015;4:212. [PMID: 26605241 DOI: 10.4103/2277-9175.166149] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
187 German AL, Fleming K, Kaye P, Davies S, Goldin R, Hubscher SG, Tiniakos D, Mcgregor A, Wyatt JI. Can reference images improve interobserver agreement in reporting liver fibrosis? J Clin Pathol 2018;71:368-71. [DOI: 10.1136/jclinpath-2017-204760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
188 Kim DB, Paik CN, Song DS, Kim YJ, Lee JM. The characteristics of small intestinal bacterial overgrowth in patients with gallstone diseases. J Gastroenterol Hepatol 2018;33:1477-84. [PMID: 29392773 DOI: 10.1111/jgh.14113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
189 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 18.5] [Reference Citation Analysis]
190 Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-Del Vallin S, Diago M, Adams LA. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. Liver Int. 2017;37:1887-1896. [PMID: 28544769 DOI: 10.1111/liv.13480] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
191 Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun 2017;1:421-8. [PMID: 29404470 DOI: 10.1002/hep4.1054] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 15.0] [Reference Citation Analysis]
192 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
193 Kallwitz ER, Tayo BO, Kuniholm MH, Cai J, Daviglus M, Cooper RS, Cotler SJ. American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults. Clin Gastroenterol Hepatol. 2019;17:2301-2309. [PMID: 30743004 DOI: 10.1016/j.cgh.2019.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
194 Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. 2012;27:420-428. [PMID: 22596186 DOI: 10.1097/hco.0b013e328354829c] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
195 Baba HA, Theurer S, Canbay A, Schwertheim S, Lainka E, Kälsch J, Wohlschläger J. [Liver transplantation. Current aspects of pretransplantation diagnosis and rejection]. Pathologe 2020;41:505-14. [PMID: 32776226 DOI: 10.1007/s00292-020-00813-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Kim TY, Song DS, Kim HY, Sinn DH, Yoon EL, Kim CW, Jung YK, Suk KT, Lee SS, Lee CH, Kim TH, Kim JH, Choe WH, Yim HJ, Kim SE, Baik SK, Lee BS, Jang JY, Suh J 3rd, Kim HS, Nam SW, Kwon HC, Kim YS, Kim SG, Chae HB, Yang JM, Sohn JH, Lee HJ, Park SH, Han BH, Choi EH, Kim CH, Kim DJ; Korean Acute-on-Chronic Liver Failure Study Group. Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition. PLoS One 2016;11:e0146745. [PMID: 26789409 DOI: 10.1371/journal.pone.0146745] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
197 Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WMS, van Leeuwen DJ; The International Liver Pathology Study Group. Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. Histopathology 2016;68:953-67. [DOI: 10.1111/his.12957] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
198 Alkhouri N, Sedki E, Alisi A, Lopez R, Pinzani M, Feldstein AE, Nobili V. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013;33:79-85. [PMID: 23146095 DOI: 10.1111/liv.12024] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 6.6] [Reference Citation Analysis]
199 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
200 Friedman SL. Focus. J Hepatol 2013;59:403-4. [PMID: 23770255 DOI: 10.1016/j.jhep.2013.06.002] [Reference Citation Analysis]
201 van Meer S, van Erpecum KJ, Sprengers D, Klümpen HJ, Jansen PL, Ijzermans JN, Siersema PD, de Man RA, Verheij J. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol 2016;28:955-62. [PMID: 27196679 DOI: 10.1097/MEG.0000000000000641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
202 Bedossa P;  FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565-575. [PMID: 24753132 DOI: 10.1002/hep.27173] [Cited by in Crossref: 285] [Cited by in F6Publishing: 264] [Article Influence: 40.7] [Reference Citation Analysis]
203 Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology 2012;46:272-84. [DOI: 10.1097/mcg.0b013e31824587e0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 26] [Article Influence: 8.9] [Reference Citation Analysis]
204 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
205 Vanderbeck S, Bockhorst J, Kleiner D, Komorowski R, Chalasani N, Gawrieh S. Automatic quantification of lobular inflammation and hepatocyte ballooning in non alcoholic fatty liver disease liver biopsies. Hum Pathol. 2015;46:767-775. [PMID: 2577603 DOI: 10.1016/j.humpath.2015.01.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
206 Li Y, Wang X, Zhang J, Zhang S, Jiao J. Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : A systematic review. Rev Endocr Metab Disord 2021. [PMID: 34396467 DOI: 10.1007/s11154-021-09681-x] [Reference Citation Analysis]
207 Reddy YK, Marella HK, Jiang Y, Ganguli S, Snell P, Podila PSB, Maliakkal B, Satapathy SK. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. J Clin Exp Hepatol. 2020;10:245-254. [PMID: 32405181 DOI: 10.1016/j.jceh.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
208 Thorp A, Stine JG. Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep 2020;19:402-11. [PMID: 33767944 DOI: 10.1007/s11901-020-00543-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
209 Lassailly G, Caiazzo R, Mathurin P, Pattou F. Reply. Gastroenterology 2016;150:284-5. [PMID: 26616571 DOI: 10.1053/j.gastro.2015.11.035] [Reference Citation Analysis]
210 Kim HJ, Joe Y, Kim S, Park S, Park J, Chen Y, Kim J, Ryu J, Cho GJ, Surh Y, Ryter SW, Kim U, Chung H. Carbon monoxide protects against hepatic steatosis in mice by inducing sestrin-2 via the PERK-eIF2α-ATF4 pathway. Free Radical Biology and Medicine 2017;110:81-91. [DOI: 10.1016/j.freeradbiomed.2017.05.026] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
211 Armstrong MJ, Houlihan DD, Rowe IA, Clausen WHO, Elbrønd B, Gough SCL, Tomlinson JW, Newsome PN. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013;37:234-42. [DOI: 10.1111/apt.12149] [Cited by in Crossref: 145] [Cited by in F6Publishing: 132] [Article Influence: 16.1] [Reference Citation Analysis]
212 Zhang J, Abbasi O, Malevanchik L, Mohan N, Denicola R, Tarangelo N, Marzio DH. Pilot study of the prevalence of binge eating disorder in non-alcoholic fatty liver disease patients. Ann Gastroenterol 2017;30:664-9. [PMID: 29118561 DOI: 10.20524/aog.2017.0200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
213 Han J, Guo X, Koyama T, Kawai D, Zhang J, Yamaguchi R, Zhou X, Motoo Y, Satoh T, Yamada S. Zonarol Protected Liver from Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in a Mouse Model. Nutrients 2021;13:3455. [PMID: 34684455 DOI: 10.3390/nu13103455] [Reference Citation Analysis]
214 Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65-S75. [PMID: 25920092 DOI: 10.1016/j.jhep.2015.02.041] [Cited by in Crossref: 170] [Cited by in F6Publishing: 151] [Article Influence: 34.0] [Reference Citation Analysis]
215 Imajo K, Yoneda M, Fujita K, Kessoku T, Tomeno W, Ogawa Y, Shinohara Y, Sekino Y, Mawatari H, Nozaki Y, Kirikoshi H, Taguri M, Toshima G, Takahashi J, Saito S, Wada K, Nakajima A. Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. J Gastroenterol 2014;49:295-304. [PMID: 23503837 DOI: 10.1007/s00535-013-0776-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
216 Nagashimada M, Ota T. Role of vitamin E in nonalcoholic fatty liver disease. IUBMB Life. 2019;71:516-522. [PMID: 30592129 DOI: 10.1002/iub.1991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
217 Liu F, Goh GB, Tiniakos D, Wee A, Leow W, Zhao J, Rao H, Wang X, Wang Q, Wan W, Lim K, Romero‐gomez M, Petta S, Bugianesi E, Tan C, Harrison SA, Anstee QM, Chang PJ, Wei L. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. Hepatology 2020;71:1953-66. [DOI: 10.1002/hep.30986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
218 Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:85-89. [PMID: 28052629 DOI: 10.1111/liv.13301] [Cited by in Crossref: 122] [Cited by in F6Publishing: 106] [Article Influence: 30.5] [Reference Citation Analysis]
219 Zhang R, Chu K, Zhao N, Wu J, Ma L, Zhu C, Chen X, Wei G, Liao M. Corilagin Alleviates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced C57BL/6 Mice by Ameliorating Oxidative Stress and Restoring Autophagic Flux. Front Pharmacol 2019;10:1693. [PMID: 32116684 DOI: 10.3389/fphar.2019.01693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
220 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475-485. [PMID: 24574716 DOI: 10.3748/wpg.v20.i2.475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
222 Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, Kava J, Bynevelt M, MacQuillan GC, Garas G, Ayonrinde OT, Mori TA, Croft KD, Niu X, Jeffrey GP, Olynyk JK. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology. 2015;61:1555-1564. [PMID: 25524401 DOI: 10.1002/hep.27662] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
223 Ao R, Wang Y, Tong J, Wang BF. Altered microRNA-9 Expression Level is Directly Correlated with Pathogenesis of Nonalcoholic Fatty Liver Disease by Targeting Onecut2 and SIRT1. Med Sci Monit. 2016;22:3804-3819. [PMID: 27756894 DOI: 10.12659/msm.897207] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
224 Xie LT, Yan CH, Zhao QY, He MN, Jiang TA. Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. World J Gastroenterol 2018; 24(9): 957-970 [PMID: 29531460 DOI: 10.3748/wjg.v24.i9.957] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
225 Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011;6:e23937. [PMID: 21886843 DOI: 10.1371/journal.pone.0023937] [Cited by in Crossref: 383] [Cited by in F6Publishing: 367] [Article Influence: 38.3] [Reference Citation Analysis]
226 Yates KP, Deppe R, Comerford M, Masuoka H, Cummings OW, Tonascia J, Chalasani N, Vuppalanchi R; NASH CRN. Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. PLoS One 2017;12:e0185813. [PMID: 29095942 DOI: 10.1371/journal.pone.0185813] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
227 Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, Hecht J, Cusi K. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:2178-2187. [PMID: 24777953 DOI: 10.1002/hep.26988] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 11.6] [Reference Citation Analysis]
228 Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int. 2013;7 Suppl 2:765-770. [PMID: 26202292 DOI: 10.1007/s12072-013-9446-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
229 Yılmaz Y, Kanı HT, Demirtaş CÖ, Kaya E, Sapmaz AF, Qutranji L, Alkayyali T, Batun KD, Batman M, Toy B, Çiftaslan A. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turk J Gastroenterol 2019;30:892-8. [PMID: 31258138 DOI: 10.5152/tjg.2019.19072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
230 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
231 Tryndyak VP, Latendresse JR, Montgomery B, Ross SA, Beland FA, Rusyn I, Pogribny IP. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol. 2012;262:52-59. [PMID: 22561871 DOI: 10.1016/j.taap.2012.04.018] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
232 Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192-202. [PMID: 25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001] [Cited by in Crossref: 175] [Cited by in F6Publishing: 164] [Article Influence: 29.2] [Reference Citation Analysis]
233 Montesi SB, Désogère P, Fuchs BC, Caravan P. Molecular imaging of fibrosis: recent advances and future directions. J Clin Invest 2019;129:24-33. [PMID: 30601139 DOI: 10.1172/JCI122132] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 22.0] [Reference Citation Analysis]
234 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
235 Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17:748-755. [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
236 Black D, Brockbank S, Cruwys S, Goldenstein K, Hein P, Humphries B. The future R&D landscape in non-alcoholic steatohepatitis (NASH). Drug Discovery Today 2019;24:560-6. [DOI: 10.1016/j.drudis.2018.09.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
237 Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, Sun X, Tong N. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:284-295. [PMID: 28065744 DOI: 10.1016/j.clinre.2016.11.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 9.8] [Reference Citation Analysis]
238 Ke Y, Liu S, Zhang Z, Hu J. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis 2021;20:55. [PMID: 34034750 DOI: 10.1186/s12944-021-01481-1] [Reference Citation Analysis]
239 Ter Horst KW, Vatner DF, Zhang D, Cline GW, Ackermans MT, Nederveen AJ, Verheij J, Demirkiran A, van Wagensveld BA, Dallinga-Thie GM, Nieuwdorp M, Romijn JA, Shulman GI, Serlie MJ. Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease. Diabetes Care 2021;44:489-98. [PMID: 33293347 DOI: 10.2337/dc20-1644] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
240 Choi JW, Lee CH, Park JS. Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction. PeerJ 2019;7:e6524. [PMID: 30867987 DOI: 10.7717/peerj.6524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
241 Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care. 2016;39:632-638. [PMID: 26861926 DOI: 10.2337/dc15-1876] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 12.2] [Reference Citation Analysis]
242 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
243 Reddy SK, Reilly C, Zhan M, Mindikoglu AL, Jiang Y, Lane BF, Alexander HR, Culpepper WJ, El-Kamary SS. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol 2014;31:971. [PMID: 24798875 DOI: 10.1007/s12032-014-0971-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
244 Vongsuvanh R, George J, McLeod D, van der Poorten D. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 2012;57:392-8. [PMID: 22521350 DOI: 10.1016/j.jhep.2012.03.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
245 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(2): 475-485 [PMID: 24574716 DOI: 10.3748/wjg.v20.i2.475] [Cited by in CrossRef: 256] [Cited by in F6Publishing: 235] [Article Influence: 36.6] [Reference Citation Analysis]
246 Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol 2021;22:e435-45. [PMID: 34592193 DOI: 10.1016/S1470-2045(21)00344-2] [Reference Citation Analysis]
247 Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:641-648. [PMID: 23075940 DOI: 10.1097/mco.0b013e328357f747] [Cited by in Crossref: 70] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
248 Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O, Pais R, Merrouche W, de Ledinghen V, Mathurin P, Ratziu V; FLIP Consortium, the FibroFrance-CPAM Group, the FibroFrance-Obese Group. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Eur J Gastroenterol Hepatol 2018;30:569-77. [PMID: 29406435 DOI: 10.1097/MEG.0000000000001064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
249 Reddy SK, Steel JL, Chen H, Demateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19. [DOI: 10.1002/hep.25536] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 13.8] [Reference Citation Analysis]
250 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Pai RK, Yerian L, Khiyami A, Sourianarayanane A, Sargent R, Hawkins C, Dasarathy S, McCullough AJ. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci. 2015;60:1825-1831. [PMID: 25708897 DOI: 10.1007/s10620-015-3529-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
251 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
252 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Reference Citation Analysis]
253 Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012;16:487-504. [PMID: 22824477 DOI: 10.1016/j.cld.2012.05.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
254 Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, Zhang H, Gao Y, Mao Y, Zhao J. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0131664. [PMID: 26121037 DOI: 10.1371/journal.pone.0131664] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
255 Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149:389-97.e10. [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043] [Cited by in Crossref: 1264] [Cited by in F6Publishing: 1171] [Article Influence: 210.7] [Reference Citation Analysis]
256 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
257 Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. Journal of Hepatology 2018;68:362-75. [DOI: 10.1016/j.jhep.2017.10.015] [Cited by in Crossref: 139] [Cited by in F6Publishing: 130] [Article Influence: 46.3] [Reference Citation Analysis]
258 Theurer S, Kälsch J, Schwertheim S, Kathemann S, Baba HA. [Histopathological diagnosis and differential diagnosis of nonalcoholic fatty liver disease]. Pathologe 2020;41:434-43. [PMID: 32533233 DOI: 10.1007/s00292-020-00800-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Bedossa P, Kleiner DE. Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 223-47. [DOI: 10.1007/978-3-319-20538-0_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
260 Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2015;100:2231-2238. [PMID: 25885947 DOI: 10.1210/jc.2015-1966] [Cited by in Crossref: 238] [Cited by in F6Publishing: 212] [Article Influence: 39.7] [Reference Citation Analysis]
261 Hernandez GV, Smith VA, Melnyk M, Burd MA, Sprayberry KA, Edwards MS, Peterson DG, Bennet DC, Fanter RK, Columbus DA, Steibel JP, Glanz H, Immoos C, Rice MS, Santiago-Rodriguez TM, Blank J, VanderKelen JJ, Kitts CL, Piccolo BD, La Frano MR, Burrin DG, Maj M, Manjarin R. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. Am J Physiol Gastrointest Liver Physiol 2020;318:G582-609. [PMID: 32003601 DOI: 10.1152/ajpgi.00344.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
262 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 238] [Article Influence: 27.2] [Reference Citation Analysis]
263 Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol. 2014;20:4702-4711. [PMID: 24782622 DOI: 10.3748/wjp.v20.i16.4702] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
264 Zhang L, Zhang Z, Li C, Zhu T, Gao J, Zhou H, Zheng Y, Chang Q, Wang M, Wu J, Ran L, Wu Y, Miao H, Zou X, Liang B. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis. Cell Mol Gastroenterol Hepatol 2021;11:697-724. [PMID: 33075563 DOI: 10.1016/j.jcmgh.2020.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
265 Jun DW. Practice Guideline for the Diagnosis and Management of Non-alcoholic Fatty Liver Disease. Korean J Gastroenterol 2012;60:64. [DOI: 10.4166/kjg.2012.60.1.64] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
266 Ortiz VE, Kwo J. Obesity: physiologic changes and implications for preoperative management. BMC Anesthesiol 2015;15:97. [PMID: 26141622 DOI: 10.1186/s12871-015-0079-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
267 Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp Clin Trials 2020;89:105922. [PMID: 31881392 DOI: 10.1016/j.cct.2019.105922] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
268 Cianfarani S, Inzaghi E, Alisi A, Germani D, Puglianiello A, Nobili V. Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. J Pediatr 2014;165:92-8. [PMID: 24607243 DOI: 10.1016/j.jpeds.2014.01.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
269 Mazhar K. The Future of Nonalcoholic Fatty Liver Disease Treatment. Med Clin North Am 2019;103:57-69. [PMID: 30466676 DOI: 10.1016/j.mcna.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
270 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatol Commun 2021;5:1810-23. [PMID: 34499435 DOI: 10.1002/hep4.1814] [Reference Citation Analysis]
271 Barb D, Bril F, Kalavalapalli S, Cusi K. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. J Clin Endocrinol Metab 2019;104:3327-36. [PMID: 30848827 DOI: 10.1210/jc.2018-02414] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 27.0] [Reference Citation Analysis]
272 Dey P, Mah E, Li J, Jalili T, Symons JD, Bruno RS. Improved hepatic γ-tocopherol status limits oxidative and inflammatory stress-mediated liver injury in db/db mice with nonalcoholic steatohepatitis. Journal of Functional Foods 2018;40:670-8. [DOI: 10.1016/j.jff.2017.12.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
273 Alkhouri N, De Vito R, Alisi A, Yerian L, Lopez R, Feldstein AE, Nobili V. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol. 2012;57:1312-1318. [PMID: 22871498 DOI: 10.1016/j.jhep.2012.07.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.7] [Reference Citation Analysis]
274 Skuratovskaia D, Komar A, Vulf M, Quang HV, Shunkin E, Volkova L, Gazatova N, Zatolokin P, Litvinova L. IL-6 Reduces Mitochondrial Replication, and IL-6 Receptors Reduce Chronic Inflammation in NAFLD and Type 2 Diabetes. Int J Mol Sci 2021;22:1774. [PMID: 33579000 DOI: 10.3390/ijms22041774] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
275 Verbeek J, Jacobs A, Spincemaille P, Cassiman D. Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis. Curr Protoc Mouse Biol 2016;6:201-10. [PMID: 27248435 DOI: 10.1002/cpmo.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
276 Schneider AL, Lazo M, Ndumele CE, Pankow JS, Coresh J, Clark JM, Selvin E. Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. Diabet Med 2013;30:926-33. [PMID: 23510198 DOI: 10.1111/dme.12187] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
277 Yue Y, Liu X, Li Y, Xia B, Yu W. The role of TLR4/MyD88/NF-κB pathway in periodontitis-induced liver inflammation of rats. Oral Dis 2021;27:1012-21. [PMID: 32853444 DOI: 10.1111/odi.13616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988-997. [PMID: 22652341 DOI: 10.1016/j.drudis.2012.05.012] [Cited by in Crossref: 175] [Cited by in F6Publishing: 160] [Article Influence: 19.4] [Reference Citation Analysis]
279 Tonomura S, Naka S, Tabata K, Hara T, Mori K, Tanaka S, Sumida Y, Kanemasa K, Nomura R, Matsumoto-Nakano M, Ihara M, Takahashi N, Nakano K. Relationship between Streptococcus mutans expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: a pilot study. BMJ Open Gastroenterol 2019;6:e000329. [PMID: 31645988 DOI: 10.1136/bmjgast-2019-000329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
280 Kessoku T, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Ogawa Y, Imajo K, Saigusa Y, Yamamoto K, Yamanaka T, Usuda H, Wada K, Yoneda M, Saito S, Nakajima A. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. BMJ Open 2020;10:e037961. [PMID: 32907904 DOI: 10.1136/bmjopen-2020-037961] [Reference Citation Analysis]
281 Francque S, Vonghia L. The future of diagnosing NASH - could a simple blood test be the key? Expert Rev Gastroenterol Hepatol 2017;11:995-7. [PMID: 28862886 DOI: 10.1080/17474124.2017.1374851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
282 Conlon BA, Beasley JM, Aebersold K, Jhangiani SS, Wylie-Rosett J. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients. 2013;5:4093-4114. [PMID: 24152749 DOI: 10.3390/nu5104093] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
283 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
284 Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
285 Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Friedman SL, Diago M, Romero-Gomez M. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology. 2016;63:1875-1887. [PMID: 26849287 DOI: 10.1002/hep.28484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
286 Browning MG, Khoraki J, DeAntonio JH, Mazzini G, Mangino MJ, Siddiqui MS, Wolfe LG, Campos GM. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes. Int J Obes (Lond). 2018;42:926-929. [PMID: 29437160 DOI: 10.1038/ijo.2017.309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
287 Francque S, Verrijken A, Caron S, Prawitt J, Paumelle R, Derudas B, Lefebvre P, Taskinen MR, Van Hul W, Mertens I, Hubens G, Van Marck E, Michielsen P, Van Gaal L, Staels B. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol 2015;63:164-73. [PMID: 25703085 DOI: 10.1016/j.jhep.2015.02.019] [Cited by in Crossref: 158] [Cited by in F6Publishing: 156] [Article Influence: 26.3] [Reference Citation Analysis]
288 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/s10620-016-4062-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
289 Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, Chim AM, Yeung DK, Yu J, Chu WC. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther. 2012;36:1057-1066. [PMID: 23066946 DOI: 10.1111/apt.12091] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
290 Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Tur JA, Abete I, Zulet MA, Martinez JA. Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. Diagnostics (Basel) 2021;11:1083. [PMID: 34199237 DOI: 10.3390/diagnostics11061083] [Reference Citation Analysis]
291 Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014;59:1617-24. [PMID: 24464211 DOI: 10.1007/s10620-014-3031-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
292 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 2013;19:216-254. [PMID: 24133661 DOI: 10.3350/cmh.2013.19.3.216] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
293 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
294 Armstrong MJ, Hazlehurst JM, Hull D, Guo K, Borrows S, Yu J, Gough SC, Newsome PN, Tomlinson JW. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014;16:651-660. [PMID: 24962805 DOI: 10.1111/dom.12272] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
295 Bugianesi E, Rosso C, Cortez-Pinto H. How to diagnose NAFLD in 2016. J Hepatol. 2016;65:643-644. [PMID: 27401791 DOI: 10.1016/j.jhep.2016.05.038] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
296 Corey KE, Stanley TL, Misdraji J, Scirica C, Pratt J, Hoppin A, Misra M. Prevalence and outcome of non-alcoholic fatty liver disease in adolescents and young adults undergoing weight loss surgery. Pediatr Obes 2014;9:e91-3. [PMID: 24677740 DOI: 10.1111/j.2047-6310.2014.219.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
297 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
298 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
299 Bhatt M, Yazdani L, Destrempes F, Allard L, Nguyen BN, Tang A, Cloutier G. Multiparametric in vivo ultrasound shear wave viscoelastography on farm-raised fatty duck livers: human radiology imaging applied to food sciences. Poult Sci 2021;100:100968. [PMID: 33607316 DOI: 10.1016/j.psj.2020.12.065] [Reference Citation Analysis]
300 Argo CK, Ikura Y, Lackner C, Caldwell SH. The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response: HEPATOLOGY, Vol. XX, No. X, 2015. Hepatology 2016;63:1056-7. [DOI: 10.1002/hep.28009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
301 Corey KE, Chalasani N. Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials? Hepatology 2011;54:1503-5. [PMID: 21953015 DOI: 10.1002/hep.24696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
302 Imajo K, Hyogo H, Yoneda M, Honda Y, Kessoku T, Tomeno W, Ogawa Y, Taguri M, Mawatari H, Nozaki Y, Fujita K, Kirikoshi H, Saito S, Sumida Y, Ono M, Wada K, Nakajima A, Eguchi Y. LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. PLoS One 2014;9:e115403. [PMID: 25541989 DOI: 10.1371/journal.pone.0115403] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
303 Brunt EM, Kleiner DE. When is it NAFLD and when is it ALD? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease. Chichester: John Wiley & Sons, Ltd; 2016. pp. 72-81. [DOI: 10.1002/9781118924938.ch9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
304 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 1009] [Article Influence: 119.8] [Reference Citation Analysis]
305 Yoon CH, Jin YJ, Lee JW. Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area. Eur J Gastroenterol Hepatol 2018;30:1090-6. [PMID: 29847489 DOI: 10.1097/MEG.0000000000001174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
306 Nakashita C, Xi L, Inoue Y, Kabura R, Masuda S, Yamano Y, Katoh T. Impact of dietary compositions and patterns on the prevalence of nonalcoholic fatty liver disease in Japanese men: a cross-sectional study. BMC Gastroenterol 2021;21:342. [PMID: 34481454 DOI: 10.1186/s12876-021-01919-x] [Reference Citation Analysis]
307 Honma Y, Sato-morita M, Katsuki Y, Mihara H, Baba R, Harada M. Trehalose activates autophagy and decreases proteasome inhibitor-induced endoplasmic reticulum stress and oxidative stress-mediated cytotoxicity in hepatocytes: Trehalose activates autophagy in hepatocytes. Hepatol Res 2018;48:94-105. [DOI: 10.1111/hepr.12892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
308 Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology. 2012;56:2221-2230. [PMID: 22767263 DOI: 10.1002/hep.25935] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
309 De Chiara F, Ureta Checcllo C, Ramón Azcón J. High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths. Nutrients 2019;11:E2985. [PMID: 31817648 DOI: 10.3390/nu11122985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
310 Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(42): 15539-15548 [PMID: 25400438 DOI: 10.3748/wjg.v20.i42.15539] [Cited by in CrossRef: 165] [Cited by in F6Publishing: 140] [Article Influence: 23.6] [Reference Citation Analysis]
311 Parker R, Hodson J, Rowe IAC. Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis. J Gastroenterol Hepatol 2017;32:950-6. [PMID: 27796056 DOI: 10.1111/jgh.13625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
312 Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, Seki E. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014;59:483-495. [PMID: 23996730 DOI: 10.1002/hep.26698] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 17.3] [Reference Citation Analysis]
313 Moretti R, Caruso P, Gazzin S. Non-alcoholic fatty liver disease and neurological defects. Ann Hepatol 2019;18:563-70. [PMID: 31080056 DOI: 10.1016/j.aohep.2019.04.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
314 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/S10620-016-4052-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
315 Liu CH, Ampuero J, Gil-Gómez A, Montero-Vallejo R, Rojas Á, Muñoz-Hernández R, Gallego-Durán R, Romero-Gómez M. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2018;69:1335-48. [PMID: 30142428 DOI: 10.1016/j.jhep.2018.08.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 14.7] [Reference Citation Analysis]
316 Corey KE, Misdraji J, Gelrud L, Zheng H, Chung RT, Krauss RM. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis. 2014;13:100. [PMID: 24952382 DOI: 10.1186/1476-511x-13-100] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
317 Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Kato J, Tokunaga S, Sugihara TA, Hara Y, Hino K, Murawaki Y. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model. PLoS One 2016;11:e0154676. [PMID: 27135827 DOI: 10.1371/journal.pone.0154676] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
318 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367-78.e5; quiz e14. [PMID: 25865049 DOI: 10.1053/j.gastro.2015.04.005] [Cited by in Crossref: 807] [Cited by in F6Publishing: 712] [Article Influence: 134.5] [Reference Citation Analysis]
319 Rizvi AA, Patti AM, Giglio RV, Nikolic D, Amato A, Al-Busaidi N, Al-Rasadi K, Soresi M, Banach M, Montalto G, Rizzo M. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther 2015;15:1391-7. [PMID: 26195184 DOI: 10.1517/14712598.2015.1067299] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
320 Zeltser N, Meyer I, Hernandez GV, Trahan MJ, Fanter RK, Abo-Ismail M, Glanz H, Strand CR, Burrin DG, La Frano MR, Manjarín R, Maj M. Neurodegeneration in juvenile Iberian pigs with diet-induced nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2020;319:E592-606. [PMID: 32744096 DOI: 10.1152/ajpendo.00120.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
321 Bai RX, Xu YY, Qin G, Chen YM, Wang HF, Wang M, Du SY. Repression of TXNIP-NLRP3 axis restores intestinal barrier function via inhibition of myeloperoxidase activity and oxidative stress in nonalcoholic steatohepatitis. J Cell Physiol 2019;234:7524-38. [PMID: 30387131 DOI: 10.1002/jcp.27513] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
322 Maggi DC, Borgonovo A, Bansho ET, Soares-silva PE, Silva TE, Colombo BS, Wildner LM, Bazzo ML, Dantas-correa EB, Narciso-schiavon JL, Schiavon LL. Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis. Annals of Hepatology 2019;18:331-7. [DOI: 10.1016/j.aohep.2018.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Lepreux S, Villeneuve J, Dewitte A, Bérard AM, Desmoulière A, Ripoche J. CD40 signaling and hepatic steatosis: Unanticipated links. Clin Res Hepatol Gastroenterol 2017;41:357-69. [PMID: 27989689 DOI: 10.1016/j.clinre.2016.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
324 Koot BG. van der Baan-Slootweg OH, Bohte AE, Nederveen AJ, van Werven JR, Tamminga-Smeulders CL, Merkus MP, Schaap FG, Jansen PL, Stoker J, Benninga MA. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity (Silver Spring). 2013;21:583-590. [PMID: 23592667 DOI: 10.1002/oby.20173] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
325 Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2019;49:702-13. [PMID: 30761572 DOI: 10.1111/apt.15153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
326 Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemporary Clinical Trials 2020;88:105889. [DOI: 10.1016/j.cct.2019.105889] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 29.0] [Reference Citation Analysis]
327 Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakır O, Dundar M, Yucesoy M. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6(8): 613-620 [PMID: 25232454 DOI: 10.4254/wjh.v6.i8.613] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
328 Sandlers Y, Shah RR, Pearce RW, Dasarathy J, McCullough AJ, Dasarathy S. Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease. J Clin Med 2020;9:E314. [PMID: 31979094 DOI: 10.3390/jcm9020314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24:537-545. [PMID: 23827477 DOI: 10.1016/j.tem.2013.05.009] [Cited by in Crossref: 106] [Cited by in F6Publishing: 101] [Article Influence: 13.3] [Reference Citation Analysis]
330 Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology 2012;56:2172-9. [PMID: 22707355 DOI: 10.1002/hep.25887] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
331 Kleiner DE, Bedossa P. Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. Gastroenterology 2015;149:1305-8. [DOI: 10.1053/j.gastro.2015.09.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
332 Working Group*. Association of Pathologists** for Guidebook of NASH and NAFLD, 2015: The Japan Society of Hepatology. Pathological Findings of NASH and NAFLD: for Guidebook of NASH and NAFLD, 2015: The Japan Society of Hepatology. Hepatol Res. 2017;47:3-10. [PMID: 27889947 DOI: 10.1111/hepr.12847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
333 Kim W. [Treatment Options in Non-alcoholic Fatty Liver Disease]. Korean J Gastroenterol 2017;69:353-8. [PMID: 28637104 DOI: 10.4166/kjg.2017.69.6.353] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
334 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7:211-217. [PMID: 27190693 DOI: 10.3349/ymj.2016.57.4.885] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
335 Kazemirad S, Zhang E, Nguyen BN, Bodson-clermont P, Destrempes F, Trudel D, Cloutier G, Tang A. Detection of Steatohepatitis in a Rat Model by Using Spectroscopic Shear-Wave US Elastography. Radiology 2017;282:726-33. [DOI: 10.1148/radiol.2016160308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
336 Ponti F, De Cinque A, Fazio N, Napoli A, Guglielmi G, Bazzocchi A. Ultrasound imaging, a stethoscope for body composition assessment. Quant Imaging Med Surg 2020;10:1699-722. [PMID: 32742962 DOI: 10.21037/qims-19-1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
337 De Lorenzo S, Tovoli F, Mazzotta A, Vasuri F, Edeline J, Malvi D, Boudjema K, Renzulli M, Jeddou H, D'Errico A, Turlin B, Cescon M, Uguen T, Granito A, Lièvre A, Brandi G. Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. Cancers (Basel) 2020;12:E3182. [PMID: 33138044 DOI: 10.3390/cancers12113182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
338 Cai C, Wang C, Ji W, Liu B, Kang Y, Hu Z, Jiang Z. Knockdown of hepatic aquaglyceroporin-9 alleviates high fat diet-induced non-alcoholic fatty liver disease in rats. Int Immunopharmacol 2013;15:550-6. [PMID: 23415870 DOI: 10.1016/j.intimp.2013.01.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
339 Ding Y, Sun X, Chen Y, Deng Y, Qian K. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Eur J Pharmacol 2015;761:405-12. [PMID: 25967348 DOI: 10.1016/j.ejphar.2015.05.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
340 Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway IB, Connolly JJ, Mentch FD, Benoit B, Niu X, Wei WQ, Carroll RJ, Pacheco JA, Harley ITW, Divanovic S, Carrell DS, Larson EB, Carey DJ, Verma S, Ritchie MD, Gharavi AG, Murphy S, Williams MS, Crosslin DR, Jarvik GP, Kullo IJ, Hakonarson H, Li R, Xanthakos SA, Harley JB; eMERGE Network. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019;17:135. [PMID: 31311600 DOI: 10.1186/s12916-019-1364-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
341 Kramer JA, Grindley J, Crowell AM, Makaron L, Kohli R, Kirby M, Mansfield KG, Wachtman LM. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Vet Pathol 2015;52:404-13. [PMID: 24913270 DOI: 10.1177/0300985814537839] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
342 Shetty A, Syn W. Current treatment options for nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 2019;35:168-76. [DOI: 10.1097/mog.0000000000000528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
343 Goldner D, Lavine JE. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158:1967-1983.e1. [PMID: 32201176 DOI: 10.1053/j.gastro.2020.01.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
344 Liu WY, Lu da J, Du XM, Sun JQ, Ge J, Wang RW, Wang R, Zou J, Xu C, Ren J. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled trial. BMC Public Health. 2014;14:48. [PMID: 24438438 DOI: 10.1186/1471-2458-14-48] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
345 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
346 Puri P, Xu J, Vihervaara T, Katainen R, Ekroos K, Daita K, Min HK, Joyce A, Mirshahi F, Tsukamoto H, Sanyal AJ. Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese. J Lipid Res 2016;57:1017-28. [PMID: 27020313 DOI: 10.1194/jlr.M066175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
347 Zhang Y, Lu D, Wang R, Fu W, Zhang S. Relationship between Muscle Mass/Strength and Hepatic Fat Content in Post-Menopausal Women. Medicina (Kaunas) 2019;55:E629. [PMID: 31554294 DOI: 10.3390/medicina55100629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
348 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015; 21(39): 11077-11087 [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 66] [Article Influence: 11.7] [Reference Citation Analysis]
349 Vos MB, Dimick-santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE, Adda N, Baldyga W, Banerjee R, Behling C, Boulos S, Burgess G, Calboli D, Charles E, Christian R, Cohen-bacrie C, Cosma-roman D, Danzer C, Delaet I, Delegge M, Dimick-santos L, Diprospero N, Donohue K, Fischer L, Fitzpatrick E, Fried M, Hagerty D, Hale P, Hildick K, Hum D, Jamil K, Jiang L, Karpen S, Kelly M, Kleiner DE, Kohli R, Kordy K, Krieger N, Lavine J, Lee L, Lefebvre E, Lopez P, Lyons E, Malahias L, Megnien S, Mehta R, Mesenbrink P, Miller V, Minnick P, Murray C, Nghiem T, Nicholson N, Noviello S, Omokaro SO, Pang W, Percival L, Peres D, Powell M, Roman D, Root M, Sampson C, Sanyal A, Schabel E, Schwarz K, Schwimmer JB, Seyedkazemi S, Shapiro D, Shringarpure R, Silberg D, Smith E, Socha P, Squires R, Szitanyi P, Taminiau J, Torstenson R, Treem W, Vig P, Vos M, Yamashita M, Zemel M. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;157:1448-1456.e1. [DOI: 10.1053/j.gastro.2019.08.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
350 Bedossa P, Poitou C, Veyrie N, Bouillot J, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56:1751-9. [DOI: 10.1002/hep.25889] [Cited by in Crossref: 387] [Cited by in F6Publishing: 355] [Article Influence: 43.0] [Reference Citation Analysis]
351 Cisilotto J, do Amaral AE, Rosolen D, Rode MP, Silva AH, Winter E, da Silva TE, Fischer J, Matiollo C, Rateke ECM, Narciso-Schiavon JL, Schiavon LL, Creczynski-Pasa TB. MicroRNA profiles in serum samples from Acute-On-Chronic Liver Failure patients and miR-25-3p as a potential biomarker for survival prediction. Sci Rep 2020;10:100. [PMID: 31919459 DOI: 10.1038/s41598-019-56630-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
352 Tête A, Gallais I, Imran M, Legoff L, Martin-Chouly C, Sparfel L, Bescher M, Sergent O, Podechard N, Lagadic-Gossmann D. MEHP/ethanol co-exposure favors the death of steatotic hepatocytes, possibly through CYP4A and ADH involvement. Food Chem Toxicol 2020;146:111798. [PMID: 33022287 DOI: 10.1016/j.fct.2020.111798] [Reference Citation Analysis]
353 Zhou IY, Catalano OA, Caravan P. Advances in functional and molecular MRI technologies in chronic liver diseases. J Hepatol 2020;73:1241-54. [PMID: 32585160 DOI: 10.1016/j.jhep.2020.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
354 Tang A, Destrempes F, Kazemirad S, Garcia-duitama J, Nguyen BN, Cloutier G. Quantitative ultrasound and machine learning for assessment of steatohepatitis in a rat model. Eur Radiol 2019;29:2175-84. [DOI: 10.1007/s00330-018-5915-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
355 Sanyal AJ; EPA-E investigators. Reply: To PMID 24818764. Gastroenterology 2015;148:262-3. [PMID: 25451655 DOI: 10.1053/j.gastro.2014.11.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
356 Staufer K, Halilbasic E, Spindelboeck W, Eilenberg M, Prager G, Stadlbauer V, Posch A, Munda P, Marculescu R, Obermayer-Pietsch B, Stift J, Lackner C, Trauner M, Stauber RE. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. United European Gastroenterol J 2019;7:1113-23. [PMID: 31662868 DOI: 10.1177/2050640619865133] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
357 Kim W, Kim BG, Lee JS, Lee CK, Yeon JE, Chang MS, Kim JH, Kim H, Yi S, Lee J, Cho J, Kim SG, Lee J, Kim YJ. Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;45:1073-83. [DOI: 10.1111/apt.13981] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
358 Shuvaev S, Akam E, Caravan P. Molecular MR Contrast Agents. Invest Radiol 2021;56:20-34. [PMID: 33074931 DOI: 10.1097/RLI.0000000000000731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
359 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8. [PMID: 19381118 DOI: 10.1002/cld.27] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
360 Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2014;12:1724-1730.e5. [DOI: 10.1016/j.cgh.2014.01.040] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
361 Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019;67:303-11. [PMID: 30309884 DOI: 10.1136/jim-2018-000864] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
362 Kage M, Aishima S, Kusano H, Yano H. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Med Ultrason (2001) 2020;47:549-54. [PMID: 33136250 DOI: 10.1007/s10396-020-01061-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Tai FW, Syn WK, Alazawi W. Practical approach to non-alcoholic fatty liver disease in patients with diabetes. Diabet Med. 2015; Feb 12. [Epub ahead of print]. [PMID: 25683343 DOI: 10.1111/dme.12725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
364 Correa CG, Colombo BDS, Ronsoni MF, Soares e Silva PE, Fayad L, Silva TE, Wildner LM, Bazzo ML, Dantas-Correa EB, Narciso-Schiavon JL, Schiavon LL. Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis. World J Hepatol 2016; 8(17): 739-748 [PMID: 27330683 DOI: 10.4254/wjh.v8.i17.739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
365 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
366 Mahawar KK, Parmar C, Graham Y, Abouleid A, Carr WRJ, Jennings N, Schroeder N, Small PK. Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base. OBES SURG 2016;26:177-81. [DOI: 10.1007/s11695-015-1916-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
367 Verbeek J, Lannoo M, Pirinen E, Ryu D, Spincemaille P, Vander Elst I, Windmolders P, Thevissen K, Cammue BPA, van Pelt J, Fransis S, Van Eyken P, Ceuterick-de Groote C, Van Veldhoven PP, Bedossa P, Nevens F, Auwerx J, Cassiman D. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. Gut 2015;64:673-83. [DOI: 10.1136/gutjnl-2014-306748] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
368 Chalasani N, Regev A. Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage? Gastroenterology 2016;151:1046-51. [PMID: 27765688 DOI: 10.1053/j.gastro.2016.10.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
369 Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 2014; 20(28): 9330-9337 [PMID: 25071327 DOI: 10.3748/wjg.v20.i28.9330] [Cited by in F6Publishing: 123] [Reference Citation Analysis]
370 Wang Y, Liu Z, Zou W, Hong H, Fang H, Tong W. Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH. Biomarkers in Medicine 2015;9:1189-200. [DOI: 10.2217/bmm.15.70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
371 Newton KP, Lavine JE, Wilson L, Behling C, Vos MB, Molleston JP, Rosenthal P, Miloh T, Fishbein MH, Jain AK, Murray KF, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. Hepatology 2021;73:937-51. [PMID: 32416645 DOI: 10.1002/hep.31317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
372 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
373 Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, Yiu KK, Yu J, Chan FK, Chan HL. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria : A randomized trial: Phyllanthus for NASH. J Gastroenterol Hepatol 2013;28:57-62. [DOI: 10.1111/j.1440-1746.2012.07286.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
374 Kim SH, Lim Y, Park JB, Kwak JH, Kim KJ, Kim JH, Song H, Cho JY, Hwang DY, Kim KS, Jung YS. Comparative study of fatty liver induced by methionine and choline-deficiency in C57BL/6N mice originating from three different sources. Lab Anim Res 2017;33:157-64. [PMID: 28747982 DOI: 10.5625/lar.2017.33.2.157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
375 Shin J, Yu JH, Jin YJ, Yim HJ, Jung YK, Yang JM, Song DS, Kim YS, Kim SG, Kim DJ, Suk KT, Yoon EL, Lee SS, Kim CW, Kim HY, Jang JY, Jeong SW. Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding. Clin Mol Hepatol 2020;26:540-53. [PMID: 32937688 DOI: 10.3350/cmh.2020.0034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
376 Bril F, Ortiz-Lopez C, Lomonaco R, Orsak B, Freckleton M, Chintapalli K, Hardies J, Lai S, Solano F, Tio F, Cusi K. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int 2015;35:2139-46. [PMID: 25847730 DOI: 10.1111/liv.12840] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
377 Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study. APMIS. 2017;125:962-973. [PMID: 29076589 DOI: 10.1111/apm.12742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
378 Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64:399-408. [PMID: 26394161 DOI: 10.1016/j.jhep.2015.08.038] [Cited by in Crossref: 174] [Cited by in F6Publishing: 159] [Article Influence: 29.0] [Reference Citation Analysis]
379 Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995. [PMID: 24189085 DOI: 10.1136/bmjopen-2013-003995] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
380 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1822] [Article Influence: 494.5] [Reference Citation Analysis]
381 Valenti L, Mendoza RM, Rametta R, Maggioni M, Kitajewski C, Shawber CJ, Pajvani UB. Hepatic Notch Signalling Correlates with Insulin Resistance and Non-Alcoholic Fatty Liver Disease. Diabetes. 2013;62:4052-4062. [PMID: 23990360 DOI: 10.2337/db13-0769] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
382 Corey KE, Misdraji J, Gelrud L, King LY, Zheng H, Malhotra A, Chung RT. Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. Dig Dis Sci 2015;60:2523-8. [PMID: 25840922 DOI: 10.1007/s10620-015-3650-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
383 Yoneda M, Imajo K, Nakajima A. Will the magnetic resonance imaging proton density fat fraction replace liver biopsy as the gold standard for detecting steatosis? Hepatobiliary Surg Nutr 2018;7:292-3. [PMID: 30221157 DOI: 10.21037/hbsn.2018.04.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
384 Filozof C, Chow SC, Dimick-Santos L, Chen YF, Williams RN, Goldstein BJ, Sanyal A. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. Hepatol Commun 2017;1:577-85. [PMID: 29404480 DOI: 10.1002/hep4.1079] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
385 Park E, Park EY. Inverse Association between Serum 25-hydroxyvitamin D Levels and Risk of Suspected Non-Alcoholic Fatty Liver Disease in Obese Population. Int J Environ Res Public Health 2021;18:8682. [PMID: 34444431 DOI: 10.3390/ijerph18168682] [Reference Citation Analysis]
386 Cho E, Yoon J, Kwak M, Jang ES, Lee J, Yu SJ, Kim YJ, Kim CY, Lee H. Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine–Choline-Deficient Diet. Dig Dis Sci 2014;59:1461-74. [DOI: 10.1007/s10620-014-3217-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
387 Linge J, Whitcher B, Borga M, Dahlqvist Leinhard O. Sub-phenotyping Metabolic Disorders Using Body Composition: An Individualized, Nonparametric Approach Utilizing Large Data Sets. Obesity (Silver Spring) 2019;27:1190-9. [PMID: 31094076 DOI: 10.1002/oby.22510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
388 Zhang GL, Zhao QY, Lin CS, Hu ZX, Zhang T, Gao ZL. Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:3951574. [PMID: 30809540 DOI: 10.1155/2019/3951574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
389 Carino A, Marchianò S, Biagioli M, Bucci M, Vellecco V, Brancaleone V, Fiorucci C, Zampella A, Monti MC, Distrutti E, Fiorucci S. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. FASEB J 2019;33:2809-22. [PMID: 30303744 DOI: 10.1096/fj.201801373RR] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
390 Angelini G, Castagneto-Gissey L, Casella-Mariolo J, Caristo ME, Russo MF, Lembo E, Verrastro O, Stefanizzi G, Marini PL, Casella G, Bornstein SR, Rubino F, Mingrone G. Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity. Am J Physiol Gastrointest Liver Physiol 2020;319:G502-11. [PMID: 32812775 DOI: 10.1152/ajpgi.00357.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
392 Corey KE, Rinella ME. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci 2016;61:1387-97. [PMID: 26942734 DOI: 10.1007/s10620-016-4083-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
393 Koot BG, de Groot E, van der Baan-Slootweg OH, Bohte AE, Nederveen AJ, Jansen PL, Stoker J, Benninga MA. Nonalcoholic fatty liver disease and cardiovascular risk in children with obesity. Obesity (Silver Spring) 2015;23:1239-43. [PMID: 25960049 DOI: 10.1002/oby.21076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
394 Wang Y, Attar BM, Hinami K, Fuentes HE, Jaiswal P, Zhang H, Simons-Linares CS, Tafur AJ. Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma. J Gastrointest Cancer 2018;49:275-82. [PMID: 28374272 DOI: 10.1007/s12029-017-9945-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
395 Ong JP, Younossi ZM. Editorial: probiotics in NASH - more studies are needed. Aliment Pharmacol Ther. 2014;40:211-212. [PMID: 24946062 DOI: 10.1111/apt.12812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
396 Amaral AED, Rode MP, Cisilotto J, Silva TED, Fischer J, Matiollo C, Morais Rateke EC, Narciso-Schiavon JL, Schiavon LL, Creczynski-Pasa TB. MicroRNA profiles in serum samples from patients with stable cirrhosis and miRNA-21 as a predictor of transplant-free survival. Pharmacol Res 2018;134:179-92. [PMID: 29935272 DOI: 10.1016/j.phrs.2018.06.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
397 Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol 2019; 25(11): 1307-1326 [PMID: 30918425 DOI: 10.3748/wjg.v25.i11.1307] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 52] [Article Influence: 31.5] [Reference Citation Analysis]
398 Yu J, Zhu C, Wang X, Kim K, Bartolome A, Dongiovanni P, Yates KP, Valenti L, Carrer M, Sadowski T, Qiang L, Tabas I, Lavine JE, Pajvani UB. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Sci Transl Med 2021;13:eabe1692. [PMID: 34162749 DOI: 10.1126/scitranslmed.abe1692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O, Pais R, Mathurin P, Ratziu V; FLIP consortium, the FibroFrance-CPAM group., FibroFrance-Obese group. Impact of steatosis and inflammation definitions on the performance of NASH tests. Eur J Gastroenterol Hepatol 2018;30:384-91. [PMID: 29280921 DOI: 10.1097/MEG.0000000000001033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
400 Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 2016;387:679-90. [DOI: 10.1016/s0140-6736(15)00803-x] [Cited by in Crossref: 762] [Cited by in F6Publishing: 330] [Article Influence: 152.4] [Reference Citation Analysis]
401 Falcon-perez JM, Royo F. Circulating RNA: looking at the liver through a frosted glass. Biomarkers 2015;20:339-54. [DOI: 10.3109/1354750x.2015.1101785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
402 Yang L, Miura K, Zhang B, Matsushita H, Yang YM, Liang S, Song J, Roh YS, Seki E. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice. Cell Mol Gastroenterol Hepatol 2017;3:469-83. [PMID: 28462384 DOI: 10.1016/j.jcmgh.2016.12.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
403 Brunt EM, Kleiner DE. Pathology of NAFLD. In: Farrell GC, Mccullough AJ, Day CP, editors. Non-Alcoholic Fatty Liver Disease. Oxford: Wiley-Blackwell; 2013. pp. 27-36. [DOI: 10.1002/9781118556153.ch3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
404 Neuschwander-Tetri BA. NASH: the tribulations of conducting NASH trials. Nat Rev Gastroenterol Hepatol 2014;11:274-6. [PMID: 24709815 DOI: 10.1038/nrgastro.2014.51] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
405 Endo Y, Ohta M, Tada K, Nakanuma H, Saga K, Masuda T, Hirashita T, Iwashita Y, Ozeki Y, Masaki T, Inomata M. Improvement of non-alcoholic fatty liver disease after laparoscopic sleeve gastrectomy in Japanese obese patients. Ann Gastroenterol Surg 2019;3:285-90. [PMID: 31131357 DOI: 10.1002/ags3.12234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
406 Hauff P, Gottwald U, Ocker M. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin Investig Drugs. 2015;24:309-327. [PMID: 25547844 DOI: 10.1517/13543784.2015.997874] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
407 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
408 Yang YM, Fukui M, Wang Z, Miao F, Karriker MJ, Seki E. Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2018;9:378. [PMID: 30083132 DOI: 10.3389/fendo.2018.00378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]